MX385409B - Proceso para manipular el nivel de contenido de glicano de una glicoproteína. - Google Patents

Proceso para manipular el nivel de contenido de glicano de una glicoproteína.

Info

Publication number
MX385409B
MX385409B MX2017006997A MX2017006997A MX385409B MX 385409 B MX385409 B MX 385409B MX 2017006997 A MX2017006997 A MX 2017006997A MX 2017006997 A MX2017006997 A MX 2017006997A MX 385409 B MX385409 B MX 385409B
Authority
MX
Mexico
Prior art keywords
manipulating
glycoprotein
content level
glycan content
glycan
Prior art date
Application number
MX2017006997A
Other languages
English (en)
Spanish (es)
Other versions
MX2017006997A (es
Inventor
Daniel R Leiske
Michael T Trentalange
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX385409(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2017006997A publication Critical patent/MX2017006997A/es
Publication of MX385409B publication Critical patent/MX385409B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2017006997A 2014-12-01 2015-12-01 Proceso para manipular el nivel de contenido de glicano de una glicoproteína. MX385409B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01
PCT/US2015/063271 WO2016089919A1 (en) 2014-12-01 2015-12-01 Process for manipulating the level of glycan content of a glycoprotein

Publications (2)

Publication Number Publication Date
MX2017006997A MX2017006997A (es) 2017-10-16
MX385409B true MX385409B (es) 2025-03-04

Family

ID=55024253

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006997A MX385409B (es) 2014-12-01 2015-12-01 Proceso para manipular el nivel de contenido de glicano de una glicoproteína.

Country Status (22)

Country Link
US (5) US10167492B2 (OSRAM)
EP (2) EP3680344A1 (OSRAM)
JP (4) JP6698681B2 (OSRAM)
KR (1) KR102623965B1 (OSRAM)
CN (1) CN107109455B (OSRAM)
AU (5) AU2015355087C1 (OSRAM)
CA (1) CA2969225C (OSRAM)
CL (1) CL2017001369A1 (OSRAM)
CY (1) CY1123247T1 (OSRAM)
DK (1) DK3227454T3 (OSRAM)
EA (2) EA202091598A3 (OSRAM)
ES (1) ES2784503T3 (OSRAM)
HU (1) HUE049201T2 (OSRAM)
IL (2) IL276165B (OSRAM)
LT (1) LT3227454T (OSRAM)
MX (1) MX385409B (OSRAM)
PL (1) PL3227454T3 (OSRAM)
PT (1) PT3227454T (OSRAM)
SG (2) SG10202002458PA (OSRAM)
SI (1) SI3227454T1 (OSRAM)
WO (1) WO2016089919A1 (OSRAM)
ZA (2) ZA201703729B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015355087C1 (en) 2014-12-01 2025-10-30 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
EP4310503A3 (en) 2015-12-30 2024-03-20 Momenta Pharmaceuticals, Inc. Methods related to biologics
US12503700B2 (en) * 2017-03-14 2025-12-23 Amgen Inc. Control of total afucosylated glycoforms of antibodies produced in cell culture
JP6943972B2 (ja) * 2017-03-31 2021-10-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 灌流培地
CN111373028B (zh) * 2017-11-30 2022-07-05 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
SG11202009216YA (en) * 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
CA3099917A1 (en) * 2018-05-24 2019-11-28 Ares Trading S.A. Method for controlling the afucosylation level of a glycoprotein composition
CA3099757A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
EP3850006A1 (en) 2018-09-11 2021-07-21 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
US11634499B2 (en) 2018-11-13 2023-04-25 Janssen Biotech, Inc. Control of trace metals during production of anti-CD38 antibodies
IL284374B2 (en) * 2018-12-31 2025-10-01 Momenta Pharmaceuticals Inc Methods for producing ozatekinumab
MX2021008983A (es) * 2019-01-30 2021-09-08 Amgen Inc Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
BR112021022202A2 (pt) 2019-05-06 2021-12-28 Amgen Inc Modulação de funções efetoras de anticorpo
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
EP4034556A1 (en) 2019-09-26 2022-08-03 Amgen Inc. Methods of producing antibody compositions
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
CA3197930A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
WO2022261021A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2023223660A1 (en) * 2022-02-25 2024-08-01 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture
AU2024256160A1 (en) 2023-04-20 2025-10-02 Amgen Inc. Methods of determining relative unpaired glycan content
WO2025036924A1 (en) * 2023-08-16 2025-02-20 Glaxosmithkline Intellectual Property Limited Method of controlling antibody glycosylation profile

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
DK0939121T4 (da) 1989-09-12 2008-02-04 Ahp Mfg B V TNF-bindende proteiner
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
EP1666591B1 (en) 1995-06-29 2011-03-23 Immunex Corporation Cytokine that induces apoptosis
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EG24459A (en) 2000-05-26 2009-07-16 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
EP2495308A1 (en) 2005-12-08 2012-09-05 Amgen Inc. Improved production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
ES2440487T3 (es) 2006-07-13 2014-01-29 Wyeth Llc Producción de glucoproteínas
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
US20100028904A1 (en) * 2007-03-30 2010-02-04 Centocor, Inc. Way to obtain high expression clones of mammalian cells using a methylcellulose with fluorescent protein a or g and fluorescent screening method
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
ES2362990T5 (es) 2007-06-15 2017-07-20 Amgen Inc. Métodos de tratamiento de medios de cultivo celular para su uso en un biorreactor
AU2010256455A1 (en) 2009-06-05 2012-01-19 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120164137A1 (en) 2010-10-20 2012-06-28 Morphotek, Inc. Anti-folate receptor alpha antibody glycoforms
US20120214204A1 (en) 2011-02-23 2012-08-23 Amgen Inc. Cell culture media for uvc exposure and methods related thereto
BR112013022832A2 (pt) * 2011-03-06 2016-11-22 Merck Serono Sa linhagens de células de baixo teor de fucose e usos das mesmas
US9133493B2 (en) 2011-04-21 2015-09-15 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
US9062106B2 (en) 2011-04-27 2015-06-23 Abbvie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20230114317A (ko) 2011-07-01 2023-08-01 암젠 인크 포유동물 세포 배양
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
BR112014008303A2 (pt) 2011-09-16 2017-04-11 Amgen Inc alimentação contínua controlada pré-programada sem feedback de culturas celulares
CN104136047B (zh) 2011-10-26 2018-02-06 安姆根有限公司 减少或消除由暴露于uv光而引起的蛋白质修饰和降解的方法
US20150119558A1 (en) * 2012-01-20 2015-04-30 Agency For Science, Technology And Research Cho-gmt recombinant protein expression
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
US10059770B2 (en) 2012-01-30 2018-08-28 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of a glycoprotein composition
US10955291B2 (en) 2012-03-15 2021-03-23 Amgen Inc. Methods of determining exposure to UV light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
JP6273205B2 (ja) * 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
BR112016001461A2 (pt) * 2013-07-23 2017-08-29 Biocon Ltd Método ou processo para modificar a fucosilação em um sistema de expressão de proteínas eucariótico e/ou eucariote, glicoproteína, e, uso de uma glicoproteína
SI3110961T1 (sl) * 2014-02-27 2020-03-31 F. Hoffmann-La Roche Ag Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
AU2015355087C1 (en) 2014-12-01 2025-10-30 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
US20210017565A1 (en) 2021-01-21
JP2017538446A (ja) 2017-12-28
ZA202006002B (en) 2022-03-30
US10822630B2 (en) 2020-11-03
WO2016089919A1 (en) 2016-06-09
IL252569B (en) 2020-08-31
CN107109455B (zh) 2022-02-18
HUE049201T2 (hu) 2020-09-28
AU2020202302A1 (en) 2020-04-23
LT3227454T (lt) 2020-07-27
CY1123247T1 (el) 2021-10-29
EP3680344A1 (en) 2020-07-15
KR102623965B1 (ko) 2024-01-11
EA201791223A1 (ru) 2017-10-31
SI3227454T1 (sl) 2020-06-30
IL252569A0 (en) 2017-07-31
US20170362625A1 (en) 2017-12-21
CA2969225C (en) 2023-08-22
SG11201704351WA (en) 2017-06-29
CL2017001369A1 (es) 2018-02-23
IL276165A (en) 2020-09-30
JP2020124216A (ja) 2020-08-20
AU2015355087B2 (en) 2020-04-09
JP7066775B2 (ja) 2022-05-13
MX2017006997A (es) 2017-10-16
PL3227454T3 (pl) 2020-07-27
EA036178B1 (ru) 2020-10-09
SG10202002458PA (en) 2020-04-29
EP3227454A1 (en) 2017-10-11
JP6698681B2 (ja) 2020-05-27
CA2969225A1 (en) 2016-06-09
EA202091598A2 (ru) 2020-10-30
JP2024095777A (ja) 2024-07-10
ZA201703729B (en) 2021-03-31
BR112017011652A2 (pt) 2018-06-26
CN107109455A (zh) 2017-08-29
AU2015355087C1 (en) 2025-10-30
US20230159974A1 (en) 2023-05-25
DK3227454T3 (da) 2020-04-14
AU2025223948A1 (en) 2025-09-18
PT3227454T (pt) 2020-04-06
AU2015355087A1 (en) 2017-06-29
US10167492B2 (en) 2019-01-01
IL276165B (en) 2022-11-01
ES2784503T3 (es) 2020-09-28
KR20170083636A (ko) 2017-07-18
EP3227454B1 (en) 2020-01-29
US20200172947A1 (en) 2020-06-04
AU2024204313A1 (en) 2024-07-11
JP2022101669A (ja) 2022-07-06
EA202091598A3 (ru) 2021-01-29
US20190085370A1 (en) 2019-03-21
AU2022200586A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
MX385409B (es) Proceso para manipular el nivel de contenido de glicano de una glicoproteína.
EP3217807A4 (en) Methods and compositions for egg white protein production
EP3119810C0 (en) METHOD FOR CARDIOVASCULAR RISK REDUCTION
LT3126395T (lt) Daugiaspecifiniai antikūnai
DK3237432T3 (da) Proteinfremstilling
EP3147369A4 (en) Fibroin-like protein production method
FI20145018A7 (fi) Menetelmä ligniinin uuttamiseksi
EP3131925A4 (en) Modified relaxin b chain peptides
PL2926674T3 (pl) Sposób wytwarzania żywności na bazie białka jaja
BR112016019389A8 (pt) Vacina, e, peptídeo
EP3133932A4 (en) Egg white processing
GB2525747B (en) Stick-resistant engine over-speed shut-down valve
TH1601003638A (th) วัสดุที่ใช้สูบแบบมีวาล์ว
TH1501001508A (th) วิธีการสำหรับการผลิตกรด l-อะมิโน
EP3221449A4 (en) Process for refolding recombinant chymotrypsin
TH1601005519B (th) ถังพักสำหรับคอมเพรสเซอร์
AU2014901409A0 (en) Modified relaxin B chain peptides
AU2014901314A0 (en) Modified relaxin B chain peptides
TH1601000293A (th) วิธีสำหรับควบคุมระดับฟิวโคสิเลชันในโปรตีน
TH1601003033A (th) วิธีในการผลิตบะหมี่กึ่งสำเร็จรูป
TH1601001854A (th) วิธีการสำหรับผลิตบะหมี่กึ่งสำเร็จรูป และบะหมี่กึ่งสำเร็จรูป
TH1601002451A (th) การพิมพ์ลายน้ำเชิงการเข้ารหัสลับของเนื้อความในการจำหน่ายเชื้อเพลิง
FI20146113A7 (fi) Proteiinien konsentrointimenetelmä
TH1501004930A (th) วิธีการสำหรับการผลิตเอธานอลโดยการใช้รีคอมบิแนนท์ ยีสต์ (recombinant yeast)
TH1501005886A (th) กระบวนการสำหรับการผลิตบิวตะไดอีน